利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.031 秒)

    Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production
    1.
    发明授权
    Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production 失效
    用于结合HTLV-III蛋白的单克隆抗体，以及用于其生产的细胞系

    公开(公告)号：US4843011A

    公开(公告)日：1989-06-27

    申请号：US816573

    申请日：1986-01-03

    申请人： Mangalasseril G. Sarngadharan ,  Fulvia di Marzo Veronese ,  Robert C. Gallo

    发明人： Mangalasseril G. Sarngadharan ,  Fulvia di Marzo Veronese ,  Robert C. Gallo

    IPC分类号： C07K16/10

    CPC分类号： C07K16/1063 ,  C07K16/1054 ,  Y10S435/81 ,  Y10S436/808 ,  Y10S436/809 ,  Y10S436/811 ,  Y10S530/808 ,  Y10S530/809 ,  Y10S530/864 ,  Y10S930/221

    摘要： Monoclonal antibodies, and hybridoma cell lines for their production, that bind with a high degree of specificity proteins associated with HTLV-III virus are presently disclosed. In particular, transmembrane envelope glycoprotein gp41 (41,000 dalton molecular size), major core antigen p24 (24,000 dalton molecular size), and p17 protein (17,000 dalton molecular size) are disclosed. The proteins to which the present monoclonal antibodies respond are essentially antigenically distinct from HTLV-I and HTLV-II. SVM-16 is an IgM monoclonal antibody, SVM-23 is an IgG.sub.2 monoclonal antibody, and SVM-26 is an IgG.sub.1 monoclonal antibody, all of which bind to p24. SVM-25 is an IgG.sub.1 monoclonal antibody binding gp41, and SVM-33 is an IgG.sub.1 monoclonal antibody binding p17. All the monoclonal antibodies of the present invention are produced in hybridoma cells prepared by fusing myeloma cells with spleen cells from mammals, such as mice, immunized with lysates of purified virus.

    摘要翻译： 目前公开了与HTLV-III病毒相关的高度特异性蛋白质结合的用于其生产的单克隆抗体和杂交瘤细胞系。 具体地，公开了跨膜包膜糖蛋白gp41（41,000道尔顿分子大小），主要核心抗原p24（24,000道尔顿分子大小）和p17蛋白（17,000道尔顿分子大小）。 本单克隆抗体应答的蛋白质本质上与HTLV-1和HTLV-II具有抗原性。 SVM-16是IgM单克隆抗体，SVM-23是IgG2单克隆抗体，SVM-26是IgG1单克隆抗体，均与p24结合。 SVM-25是结合gp41的IgG1单克隆抗体，SVM-33是结合p17的IgG1单克隆抗体。 将本发明的所有单克隆抗体产生于通过将骨髓瘤细胞与来自哺乳动物（例如用纯化病毒的裂解物免疫的）的小鼠的脾细胞融合而制备的杂交瘤细胞中。

    Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
    6.
    发明授权
    Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions 失效
    血清学检测艾滋病和艾滋病前期患者血清中HTLV-III的抗体

    公开(公告)号：US4520113A

    公开(公告)日：1985-05-28

    申请号：US602945

    申请日：1984-04-23

    申请人： Robert C. Gallo ,  Mikulas Popovic ,  Mangalasseril G. Sarngadharan

    发明人： Robert C. Gallo ,  Mikulas Popovic ,  Mangalasseril G. Sarngadharan

    IPC分类号： G01N33/543 ,  A61K39/00 ,  C12N7/04 ,  C12Q1/70 ,  G01N33/569 ,  G01N33/54 ,  G01N33/56

    CPC分类号： G01N33/56988 ,  Y10S435/81 ,  Y10S435/948 ,  Y10S435/974 ,  Y10S435/975 ,  Y10S436/804 ,  Y10S436/808 ,  Y10S436/809 ,  Y10S436/811

    摘要： This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.

    摘要翻译： 本发明涉及艾滋病和艾滋病前期患者血清中抗体的检测，并描述了与病毒HTLV-III人T细胞白血病病毒相关的抗原的生物化学和免疫学分析。 显示出与该病毒感染人细胞相关的抗原由AIDS患者的抗体特异性地识别。 具体来说，艾滋病患者分离出来的并通过HT细胞系共培养传播的HTLV-III由来自艾滋病患者的人血清的抗体特异性检测。 检测抗体的方法优选是基于Western Blot技术或ELISA（酶联免疫吸附测定）或间接免疫荧光测定的条带放射免疫测定（RIA）。

    Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
    7.
    发明授权
    Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) 有权
    衍生自命名为雌激素（MA）的新型早期妊娠因子的生物活性多肽

    公开(公告)号：US07994278B1

    公开(公告)日：2011-08-09

    申请号：US09632831

    申请日：2000-08-04

    申请人： Robert C. Gallo ,  Joseph Bryant ,  Yanto Lundardi-Iskandar

    发明人： Robert C. Gallo ,  Joseph Bryant ,  Yanto Lundardi-Iskandar

    IPC分类号： A61K38/00 ,  A61K38/04

    CPC分类号： C07K16/26 ,  A61K38/00 ,  A61K48/00 ,  C07K14/59 ,  C07K2319/00

    摘要： The invention relates to therapeutic polypeptides isolated from beta-human chorionic gonadotropin (β-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.

    摘要翻译： 本发明涉及从人类早孕尿中发现的β-人绒毛膜促性腺激素（＆bgr--hCG）分离的治疗性多肽，现在合成产生并命名为Maternin。 治疗性多肽及其功能等同物可用于治疗和/或预防各种医疗状况。 治疗性多肽的治疗效果的实例包括抗HIV，抗癌，抗浪费，造血（例如，贫血，辐射介导的骨髓损伤和创伤介导的失血）和抗血管生成作用。 本发明还提供了包含治疗性多肽的药物组合物，以及使用治疗性多肽，功能等同物和/或药物组合物治疗和/或预防这些医学病症的方法。

    Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
    10.
    发明授权
    Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin 失效
    使用人绒毛膜促性腺激素衍生物促进造血的方法

    公开(公告)号：US5968513A

    公开(公告)日：1999-10-19

    申请号：US709924

    申请日：1996-09-09

    申请人： Robert C. Gallo ,  Joseph Bryant ,  Yanto Lunardi-Iskandar

    发明人： Robert C. Gallo ,  Joseph Bryant ,  Yanto Lunardi-Iskandar

    IPC分类号： A61K38/00 ,  A61K38/24 ,  A61K48/00 ,  A61K38/12 ,  C07K7/64

    CPC分类号： A61K38/24 ,  A61K48/00 ,  Y10S514/885

    摘要： The present invention relates to methods of treating or preventing diseases or disorders associated with hematopoietic deficiency by administration of human chorionic gonadotropin, .beta.-human chorionic gonadotropin or a peptide containing a sequence of a portion of .beta.-human chorionic gonadotropin. The invention also relates to methods of treating or preventing diseases or disorders associated with hematopoietic deficiency by administration of hematopoietic cells, the numbers of which have been increased by contacting the cells with human chorionic gonadotropin, .beta.-human chorionic gonadotropin or a peptide containing a sequence of a portion of .beta.-human chorionic gonadotropin. The invention also provides assays for the utility of particular human chorionic gonadotropin preparations in the treatment or prevention of hematopoietic deficiencies or in the increasing of hematopoietic cell numbers in vitro. Pharmaceutical compositions and methods of administration of are also provided.

    摘要翻译： 本发明涉及通过施用人绒毛膜促性腺激素，β-人绒毛膜促性腺激素或含有一部分β-人绒毛膜促性腺激素序列的肽来治疗或预防与造血缺陷相关的疾病或病症的方法。 本发明还涉及通过给予造血细胞来治疗或预防与造血缺陷相关的疾病或病症的方法，所述造血细胞的数量通过使细胞与人绒毛膜促性腺激素接触而增加，β-人绒毛膜促性腺激素或含有序列的肽 的一部分β-人绒毛膜促性腺激素。 本发明还提供特异性人绒毛膜促性腺激素制剂用于治疗或预防造血缺陷或增加体外造血细胞数量的测定。 还提供了药物组合物和给药方法。